Progenics Pharmaceuticals (NASDAQ:PGNX)‘s stock had its “buy” rating restated by equities researchers at Cantor Fitzgerald in a note issued to investors on Wednesday, January 17th. They presently have a $15.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 176.75% from the company’s previous close.
PGNX has been the subject of several other research reports. ValuEngine downgraded Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, October 6th. Zacks Investment Research downgraded Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 18th. Finally, BidaskClub raised Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 9th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $12.35.
Progenics Pharmaceuticals (NASDAQ:PGNX) traded up $0.07 on Wednesday, reaching $5.42. 1,251,884 shares of the company traded hands, compared to its average volume of 1,510,000. Progenics Pharmaceuticals has a 1-year low of $4.60 and a 1-year high of $11.72. The company has a debt-to-equity ratio of 0.80, a current ratio of 7.86 and a quick ratio of 7.86. The company has a market capitalization of $380.86, a PE ratio of -6.86 and a beta of 3.40.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.